Head to Head Survey: Newron Pharmaceuticals (OTCMKTS:NWPHF) and AEON Biopharma (NASDAQ:AEON)

AEON Biopharma (NASDAQ:AEON) and Newron Pharmaceuticals (OTCMKTS:NWPHF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Institutional & Insider Ownership

22.8% of AEON Biopharma shares are owned by institutional investors. 23.5% of AEON Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares AEON Biopharma and Newron Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Newron Pharmaceuticals	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent recommendations for AEON Biopharma and Newron Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0	0	1	0	3.00
Newron Pharmaceuticals	0	0	0	0	0.00

AEON Biopharma presently has a consensus target price of $5.00, indicating a potential upside of 759.25%. Given AEON Biopharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe AEON Biopharma is more favorable than Newron Pharmaceuticals.

Earnings and Valuation

This table compares AEON Biopharma and Newron Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63 million	$0.18	3.23
Newron Pharmaceuticals	$6.82 million	24.50	-$17.63 million	N/A	N/A

Newron Pharmaceuticals has higher revenue and earnings than AEON Biopharma.

Volatility & Risk

AEON Biopharma has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Newron Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Summary

AEON Biopharma beats Newron Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

About AEON Biopharma

AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.